Phase III Data Back Keryx's Plan To Expand Auryxia Market
This article was originally published in Scrip
Executive Summary
Keryx Biopharmaceuticals Inc. had a rough first year of sales for its oral, iron-based phosphate binder Auryxia (ferric citrate), but the company and it investors have high hopes that new Phase III data will support approval for a second indication that could double the drug's market.